Richard Close: And just as a follow-up, is it portend, I guess, maybe an acceleration in the adoption of the Performance Suite versus maybe just tech and services?
Seth Blackley: It’s a good question. I don’t know if I could forecast it one way or the other on that front. I think the way we’ve thought about the business, I don’t feel a huge shift in mix right now. It’s a fair bit of growth on both sides, Richard. And I think it tends to be a little bit more client specific as so they need to guarantee or are they okay with the tech services platform.
Richard Close: Okay, thank you.
Seth Blackley: You’re welcome.
Operator: [Operator Instructions] The next question comes from Jailendra Singh with Truist. Please go ahead.
Jailendra Singh: Thank you and thanks for taking my question. Actually, first quick kind of clarifying question on Molina partnership in Florida. I believe you said like 100,000 Medicare lives at typical Medicaid PMPM. Our understanding is Molina has close to 175,000 lives. Maybe they include duals and long-term care lives there, maybe those are not part of the contract? And if so, do those remain a future opportunity for you guys? And any color on PMPM for exchange lives? Is that comparable to Medicaid PMPMs?
John Johnson: Yes. Two things there, Jailendra, we only do Performance Suite for adults, not peds. That’s likely the distinction. I would also say that as we think about this for next year, of course, we are including an allowance for redetermination impact, right. So those two things are important. As you look at aggregate size of that potential partnership, we would scope it likely over $20 million at top line.
Jailendra Singh: Okay. Exchange PMPM, how much is that?
John Johnson: We typically don’t do that granular. That gets pretty nuanced, Jailendra.
Jailendra Singh: Okay, all right. Maybe in my follow-up on the comments around oncology cost trends. Clearly, you guys have seen pretty stable trends. But as you pointed out, some commentaries have been pretty mixed from some entities. Have you guys done any analysis on the cancer screening data for your population, which keeps you comfort that you never saw screening go down. So any such cost is unlikely to pick up in the future? And a quick follow-up on your earlier comment that you had corridor around your prevalence of cancer rates. But are there any protection around the acuity mix, like more late-stage cancer cases versus early stage cancer cases?
John Johnson: Let me try to take those in turn. On screening, we don’t take risk on screenings and so don’t tend to have access to that data. What we do have access to is both in conversations with our partners and broad-based research, the report that Epic put out, for example, back in February, indicated what we have seen and we’ve heard from our partners, which is the cancer screenings, in particular, in Medicare, Medicaid have been at sort of normal rates for quite some time. And so that to us is pretty definitive. And it’s consistent with what we’re seeing in our data around aggregate prevalence and acuity. On the second question, the answer is yes. The specifics, as you can imagine, in a risk contract like this get pretty nuanced around specifically how we work with our partner to ensure that we’re fairly sharing the value that we’re creating as a population might shift over time.
And so the headline just as we talked about corridors around prevalence and other items is that we’re seeking to drive aligned partnerships with risk-bearing health plans. And that model to-date has generated both significant profits and significant growth.
Jailendra Singh: Okay. And then my final question on your MSSP business. CMS came out with some changes in their proposal under financial fee schedule. It looks like they’re encouraging more ACO participation. Can you talk about your thoughts on the changes included in the proposal and does that change your view on how you plan to approach your MSSP business next year? And on the same topic, any visibility on improvement in MSSP savings for 2022 plan year and expectations this year?
